Advertisement
Australia markets open in 9 hours 4 minutes
  • ALL ORDS

    8,065.50
    +113.20 (+1.42%)
     
  • AUD/USD

    0.6622
    -0.0004 (-0.05%)
     
  • ASX 200

    7,793.30
    +110.90 (+1.44%)
     
  • OIL

    77.81
    -0.67 (-0.85%)
     
  • GOLD

    2,329.00
    -2.20 (-0.09%)
     
  • Bitcoin AUD

    96,155.07
    -51.97 (-0.05%)
     
  • CMC Crypto 200

    1,311.10
    -54.02 (-3.96%)
     

Some Analytica (ASX:ALT) Shareholders Have Taken A Painful 87% Share Price Drop

Analytica Limited (ASX:ALT) shareholders should be happy to see the share price up 17% in the last week. But will that repair the damage for the weary investors who have owned this stock as it declined over half a decade? Probably not. Indeed, the share price is down a whopping 87% in that time. So we don't gain too much confidence from the recent recovery. The million dollar question is whether the company can justify a long term recovery.

We really feel for shareholders in this scenario. It's a good reminder of the importance of diversification, and it's worth keeping in mind there's more to life than money, anyway.

See our latest analysis for Analytica

ADVERTISEMENT

We don't think Analytica's revenue of AU$811,279 is enough to establish significant demand. This state of affairs suggests that venture capitalists won't provide funds on attractive terms. As a result, we think it's unlikely shareholders are paying much attention to current revenue, but rather speculating on growth in the years to come. Investors will be hoping that Analytica can make progress and gain better traction for the business, before it runs low on cash.

Companies that lack both meaningful revenue and profits are usually considered high risk. You should be aware that there is always a chance that this sort of company will need to issue more shares to raise money to continue pursuing its business plan. While some such companies do very well over the long term, others become hyped up by promoters before eventually falling back down to earth, and going bankrupt (or being recapitalized). Some Analytica investors have already had a taste of the bitterness stocks like this can leave in the mouth.

Analytica had cash in excess of all liabilities of just AU$1.2m when it last reported (June 2019). So if it has not already moved to replenish reserves, we think the near-term chances of a capital raising event are pretty high. That probably explains why the share price is down 34% per year, over 5 years . You can see in the image below, how Analytica's cash levels have changed over time (click to see the values). You can click on the image below to see (in greater detail) how Analytica's cash levels have changed over time.

ASX:ALT Historical Debt, January 27th 2020
ASX:ALT Historical Debt, January 27th 2020

Of course, the truth is that it is hard to value companies without much revenue or profit. Would it bother you if insiders were selling the stock? It would bother me, that's for sure. It only takes a moment for you to check whether we have identified any insider sales recently.

A Different Perspective

Analytica shareholders are down 30% for the year, but the market itself is up 25%. Even the share prices of good stocks drop sometimes, but we want to see improvements in the fundamental metrics of a business, before getting too interested. However, the loss over the last year isn't as bad as the 33% per annum loss investors have suffered over the last half decade. We would want clear information suggesting the company will grow, before taking the view that the share price will stabilize. I find it very interesting to look at share price over the long term as a proxy for business performance. But to truly gain insight, we need to consider other information, too. For example, we've discovered 5 warning signs for Analytica (3 are potentially serious!) that you should be aware of before investing here.

Analytica is not the only stock insiders are buying. So take a peek at this free list of growing companies with insider buying.

Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on AU exchanges.

If you spot an error that warrants correction, please contact the editor at editorial-team@simplywallst.com. This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Simply Wall St has no position in the stocks mentioned.

We aim to bring you long-term focused research analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Thank you for reading.